Rai Gopal, Yadav Awesh K, Jain Narendra K, Agrawal Govind P
a Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences , Dr. Hari Singh Gour University , Sagar , India.
Drug Dev Ind Pharm. 2015;41(12):2018-28. doi: 10.3109/03639045.2015.1044901. Epub 2015 May 26.
Enteric-coated epichlorohydrin crosslinked dextran microspheres containing 5-Fluorouracil (5-FU) for colon drug delivery was prepared by emulsification-crosslinking method. The formulation variables studied includes different molecular weights of dextran, volume of crosslinking agent, stirring speed, time and temperature. Dextran microspheres showed mean entrapment efficiencies ranging between 77 and 87% and mean particle size ranging between 10 and 25 µm. About 90% of drug was released from uncoated dextran microspheres within 8 h, suggesting the fast release and indicated the drug loaded in uncoated microspheres, released before they reached colon. Enteric coating (Eudragit-S-100 and Eudragit-L-100) of dextran microspheres was performed by oil-in-oil solvent evaporation method. The release study of 5-FU from coated dextran microspheres was complete retardation in simulated gastric fluid (pH 1.2) and once the coating layer of enteric polymer was dissolved at higher pH (7.4 and 6.8), a controlled release of the drug from the microspheres was observed. Further, the release of drug was found to be higher in the presence of dextranase and rat caecal contents, indicating the susceptibility of dextran microspheres to colonic enzymes. Organ distribution and pharmacokinetic study in albino rats was performed to establish the targeting potential of optimized formulation in the colon.
采用乳化交联法制备了含5-氟尿嘧啶(5-FU)的肠溶包衣环氧氯丙烷交联葡聚糖微球用于结肠给药。所研究的处方变量包括不同分子量的葡聚糖、交联剂体积、搅拌速度、时间和温度。葡聚糖微球的平均包封率在77%至87%之间,平均粒径在10至25μm之间。约90%的药物在8小时内从未包衣的葡聚糖微球中释放出来,表明释放速度快,且表明未包衣微球中负载的药物在到达结肠之前就已释放。通过油包油溶剂蒸发法对葡聚糖微球进行肠溶包衣(Eudragit-S-100和Eudragit-L-100)。5-FU从包衣葡聚糖微球中的释放研究表明,在模拟胃液(pH 1.2)中完全延迟释放,一旦肠溶聚合物包衣层在较高pH值(7.4和6.8)下溶解,就会观察到药物从微球中的控释。此外,发现葡聚糖酶和大鼠盲肠内容物存在时药物释放较高,表明葡聚糖微球对结肠酶敏感。对白化大鼠进行了器官分布和药代动力学研究,以确定优化制剂在结肠中的靶向潜力。